Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsClaire Gallois, Julien Taı̈eb, Daniel G. Haller et al.|Journal of Clinical Oncology|2022Cited by 50
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.Alberto F. Sobrero, Qian Shi, Thierry André et al.|Journal of Clinical Oncology|2020Cited by 36
Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.Claire Gallois, Julien Taı̈eb, Qian Shi et al.|Journal of Clinical Oncology|2022Cited by 8
Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.Elisa Fontana, Jeffrey P. Meyers, Alberto F. Sobrero et al.|Journal of Clinical Oncology|2021Cited by 2